Published in

Taylor and Francis Group, Leukemia & Lymphoma, p. 1-9, 2024

DOI: 10.1080/10428194.2024.2313628

Links

Tools

Export citation

Search in Google Scholar

A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma

Journal article published in 2024 by Isha Mol ORCID, Yannan Hu, Thomas W. LeBlanc ORCID, Joseph C. Cappelleri, Haitao Chu ORCID, Guido Nador, Didem Aydin, Alex Schepart ORCID, Patrick Hlavacek
Distributing this paper is prohibited by the publisher
Distributing this paper is prohibited by the publisher

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO